A Narrative Review of Biologic Therapies for Type 2 Inflammation in Severe Asthma and Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): Mechanisms, Efficacy, and Safety.

Cureus · 2026 · PMC13322736 · PMID 42388935

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

For the most severe exacerbations requiring hospitalization, SIROCCO demonstrated a 52% reduction with benralizumab (0.07 vs 0.14 per year, rate ratio 0.48, 95% CI 0.22-1.03), though this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.